ertapenem (invanz) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Ertapenem is a carbapenem antibiotic marketed by Merck as Invanz. The bactericidal activity of ertapenem results from the inhibition of cell wall synthesis and is mediated through ertapenem binding to penicillin binding proteins (PBPs). In Escherichia coli, it has strong affinity toward PBPs 1a, 1b, 2, 3, 4 and 5 with preference for PBPs 2 and 3. Ertapenem has been designed to be effective against Gram-negative and Gram-positive bacteria. The most common drug-related adverse experiences in patients treated with INVANZ, including those who were switched to therapy with an oral antimicrobial, were diarrhea (5.5%), infused vein complication (3.7%), nausea (3.1%), headache (2.2%), vaginitis in females (2.1%), phlebitis/thrombophlebitis (1.3%), and vomiting (1.1%). The coadministration with probenecid to extend the half-life of ertapenem is not recommended.   NCATS

Chemistry

  • SMILES: C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](C(=O)Nc4cccc(C(=O)O)c4)C3)[C@H](C)[C@H]12
  • InChIKey: JUZNIMUFDBIJCM-ANEDZVCMSA-N
  • Mol. Mass: 475.52
  • ALogP: 0.94
  • ChEMBL Molecules:
    ertapenem  
    ertapenem sodium  
    ertapenem sodium  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$48.3070 - $104.7350
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

(1r,5s,6s,8r,2's,4's)-2-(2-(3-carboxyphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid | (4r,5r,6s)-3-((3s,5s)-5-((3-carboxyphenyl)carbamoyl)pyrrolidin-3-yl)sulfanyl-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid | (4r,5s,6s)-3-((3s,5s)-5-((3-carboxyphenyl)carbamoyl)pyrrolidin-3-ylthio)-6-((r)-1-hydroxyethyl)-4-methyl-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid | ertapenem | ertapenem disodium | ertapenem sodium | invanoz | invanz | l 749345 | l-749,345 | mk-0826

Organizations (75)

Research & Development (68)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (8)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (53)

Approved Indications (7)


 

Infections

Intraabdominal Infections (approved 2001)

Osteomyelitis

Pelvic Infection (approved 2001)

Pneumonia (approved 2001)

Skin Diseases, Bacterial (approved 2001)

Urinary Tract Infections (approved 2001)

Experimental Indications - Clinical Trial Phases 1-4 (52)


 

Acute Disease (Phase 4)

Acute Kidney Injury (Phase 4)

Anti-Infective Agents, Urinary (Phase 2/Phase 3)

Appendicitis (Phase 2)

Bacteremia (Phase 3)

Bacterial Infections (Phase 4)

Burns (Phase 4)

Carbapenems (Phase 4)

Clinical Trial (Phase 4)

Colonic Neoplasms (Phase 4)

Colorectal Surgery (Phase 3)

Community-Acquired Infections (Phase 3)

Diabetes Mellitus (Phase 3)

Diabetic Foot (Phase 3)

Diverticulitis, Colonic (Phase 4)

Diverticulosis, Colonic (Phase 4)

Drug Resistance, Bacterial (Phase 4)

Endometritis (Phase 1)

Enterobacteriaceae Infections (Phase 4)

Escherichia coli Infections (Phase 4)

Esophageal and Gastric Varices (Phase 4)

Fever (Phase 4)

Gonorrhea (Phase 3)

Healthy Volunteers (Phase 4)

Hypersensitivity (Phase 4)

Hypersensitivity, Immediate (Phase 4)

Infections ()

Intraabdominal Infections (Phase 4)

Kidney Failure, Chronic (Phase 4)

Kidney Transplantation (Phase 2/Phase 3)

Klebsiella Infections (Phase 2/Phase 3)

Klebsiella pneumoniae (Phase 4)

Liver Cirrhosis (Phase 4)

Osteomyelitis (Phase 3)

Pelvic Infection (Phase 2)

Peritoneal Dialysis, Continuous Ambulatory (Phase 4)

Peritonitis (Phase 4)

Pharmacological and Toxicological Phenomena (Phase 4)

Plasma (Phase 4)

Pneumonia (Phase 3)

Pneumonia, Bacterial (Phase 2)

Prostatic Neoplasms (Phase 4)

Pyelonephritis (Phase 3)

Rectal Neoplasms (Phase 4)

Sepsis (Phase 4)

Soft Tissue Infections (Phase 2)

Staphylococcal Infections (Phase 2)

Surgical Wound Infection (Phase 3)

Tuberculosis (Phase 2)

Tuberculosis, Pulmonary (Phase 2)

Urinary Bladder Neoplasms (Phase 4)

Urinary Tract Infections (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 70
  • # of Trial Organizations: 68

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue